Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | DGKA | P23743 | 2/20 | 0.62 |
| ▸ | PRKCA | P17252 | 3/20 | 0.60 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.60 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.60 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.60 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.59 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.59 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.59 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.59 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.59 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.59 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propylene Glycol Monostearate SCHEMBL4429462 | 1.00 | MAPT (1.00) | MAPTLMNAKDM4EDUSP3MEN1 | |
| SCHEMBL141668 | 1.00 | MAPT (1.00) | MAPTLMNAKDM4EDUSP3MEN1 | |
| SCHEMBL1730481 | 1.00 | MAPT (1.00) | MAPTLMNAKDM4EDUSP3MEN1 | |
| SCHEMBL29649070 | 1.00 | MAPT (1.00) | MAPTLMNAKDM4EDUSP3MEN1 | |
| SCHEMBL180498 | 1.00 | MAPT (1.00) | MAPTLMNAKDM4EDUSP3MEN1 | |
| SCHEMBL629794 | 1.00 | MAPT (1.00) | MAPTLMNAKDM4EDUSP3MEN1 | |
| SCHEMBL26974 | 1.00 | MAPT (1.00) | MAPTLMNAKDM4EDUSP3MEN1 | |
| Propylene Glycol Monostearate SCHEMBL35521 | 1.00 | MAPT (1.00) | MAPTLMNAKDM4EDUSP3MEN1 | |
| SCHEMBL16458 | 1.00 | MAPT (1.00) | MAPTLMNAKDM4EDUSP3MEN1 | |
| SCHEMBL1173237 | 1.00 | MAPT (1.00) | MAPTLMNAKDM4EDUSP3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 214 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3458015-B1 | VAGINAL DELIVERY SYSTEMS CONTAINING SELECTIVE ESTROGEN RECEPTOR MODULATOR (SERM) AND USES THEREOF | AZURE BIOTECH INC (US) | 2025-07-02 | — | — | EP | claimed |
| CN-118948631-B | Oil-in-water cleansing composition | 深圳市护家科技有限公司 | 2025-02-14 | — | — | CN | claimed |
| CN-118948631-A | Oil-in-water cleansing composition | 深圳市护家科技有限公司 | 2024-11-15 | — | — | CN | claimed |
| CN-116370328-A | Skin care composition and external skin preparation | 深圳市护家科技有限公司 | 2023-07-04 | — | — | CN | claimed |
| US-20230060820-A1 | OCTENIDINE SALT ANTIMICROBIAL MEDICAL ARTICLES | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2023-03-02 | — | — | US | claimed |
| CN-109640958-B | Vaginal delivery system comprising a Selective Estrogen Receptor Modulator (SERM) and uses thereof | 蔚蓝生物技术股份有限公司 | 2022-11-22 | — | — | CN | claimed |
| CN-114901069-A | Octenidine salt antimicrobial medical articles | 3M创新有限公司 | 2022-08-12 | — | — | CN | claimed |
| US-20220062374-A1 | COMPOSITIONS COMPRISING CYCLOSPORIN | Sublimity Therapeutics Limited (IE) | 2022-03-03 | — | — | US | claimed |
| EP-3881829-A1 | COMPOSITIONS COMPRISING CYCLOSPORIN | Sublimity Therapeutics Limited (IE) | 2021-09-22 | — | — | EP | claimed |
| WO-2021137102-A1 | OCTENIDINE SALT ANTIMICROBIAL MEDICAL ARTICLES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2021-07-08 | — | — | WO | claimed |
| WO-2015067762-A1 | FORMULATIONS COMPRISING CYCLOSPORIN A | SIGMOID PHARMA LIMITED (IE) | 2015-05-14 | — | — | WO | claimed |
| WO-2015067763-A1 | FORMULATIONS | SIGMOID PHARMA LIMITED (IE) | 2015-05-14 | — | — | WO | claimed |
| WO-2014201541-A1 | NON-AEROSOL FOAMS FOR TOPICAL ADMINISTRATION | CONTRACT PHARMACEUTICALS LIMITED (CA) | 2014-12-24 | — | — | WO | claimed |
| EP-1800650-B2 | Cosmetic composition providing a voluminous effect | OREAL (FR) | 2013-08-14 | — | — | EP | claimed |
| EP-1800649-B2 | Cosmetic composition with volumising effect | OREAL (FR) | 2012-10-10 | — | — | EP | claimed |
| WO-2011101239-A2 | COSMETIC OR DERMATOLOGICAL USES OF A POWDER COMPRISING A FILLER, AN ESSENTIAL OIL AND A HYDROXYLATED ESTER OF POLYOL AND OF C4 TO C16 CARBOXYLIC ACID(S) | L'OREAL (FR) | 2011-08-25 | — | — | WO | claimed |
| EP-1800650-B1 | Cosmetic composition providing a voluminous effect | OREAL (FR) | 2010-11-03 | — | — | EP | claimed |
| EP-1800649-B1 | Cosmetic composition with volumising effect | OREAL (FR) | 2008-12-10 | — | — | EP | claimed |
| US-20070196301-A1 | Cosmetic composition with a volumizing effect | L'OREAL (FR) | 2007-08-23 | — | — | US | claimed |
| US-20070141003-A1 | Cosmetic composition with a volumizing effect | L'OREAL (FR) | 2007-06-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070196301-A1 | Cosmetic composition with a volumizing effect | LIPA, CUTA, LIPG | MAPT 3816/4885LMNA 388/4885KDM4E 3219/4885 |
| US-20070141003-A1 | Cosmetic composition with a volumizing effect | CUTA, ELOVL1, LIPA | MAPT 3454/4885LMNA 483/4885KDM4E 2977/4885 |
| US-20220062374-A1 | COMPOSITIONS COMPRISING CYCLOSPORIN | MALT1, SI, TPMT | MAPT 2621/4885LMNA 2644/4885KDM4E 2989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.